CLL
From the Journals
Stopping venetoclax treatment early reduces CLL survival outcomes
Survival outcomes are decreased with early, permanent discontinuation of venetoclax but unchanged by treatment interruption, regardless of...
News
FDA investigates possible increased risk of death with lymphoma drug
Clinical trial findings of “possible increased risk of death” associated with the drug umbralisib for CLL prompted the FDA to announce...
From the Journals
CLL patients ‘cured’: 10 years post infusion, CAR T cells persist
A decade after CAR T’cell treatment, chronic leukemia patients reported “cured,” with cells still detectable.
Feature
100 coauthored papers, 10 years: Cancer transplant pioneers model 'team science'
MSKCC medical oncologists share expertise in HSCT, Spanish background, a gift for mentoring, and 100 peer-reviewed publications written together...
Feature
Rituximab and COVID-19 vaccines: Studies begin to answer key questions
This article aims to summarize the latest research on how rituximab affects humoral and cell-mediated response following a COVID-19 vaccine...
From the Journals
‘Highly encouraging’ MRD results for zanubrutinib add-on in CLL
Blood and bone marrow MRD was undetectable in almost 90% of subjects after a median of 10 treatment cycles.
From the Journals
CLL and COVID-19: Outcome trends and lessons learned
Data highlight opportunities for further investigation into optimal management of COVID-19, immune response after infection, and effective...
From the Journals
Venetoclax heralded a new class of small-molecule blood cancer drugs
BCL2 inhibitor venetoclax has been quickly followed by drugs that target either BCL2 or proteins with similar prosurvival function, especially...
Latest News
New trials in leukemia: Could your patient benefit?
Late-phase trials are opening up for leukemia patients aged 1-65 years.
Latest News
Decades spent searching for genes linked to rare blood cancer
Tantalizing clues about WM and related B-cell cancers have emerged.
From the Journals
BTKi resistance: ‘Achilles’ heel’ in effective treatment of B-cell malignancies
Success of BTKi in treating lymphoid malignancies is marred by resistance